Recently, a large multicenter trial including 1955 patients prior to initial prostate biopsy compared performance of urinary HOXC6 and DLX1 mRNA (combined with other risk factors) with Prostate Cancer Prevention Trial Risk Calculator (PCPTRC). This evidence concerns the gene DLX1 and prostate carcinoma.